Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Targeting Tumor Markers with Antisense Peptides: An Example of Human Prostate Specific Antigen (CROSBI ID 267152)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Štambuk, Nikola ; Konjevoda, Paško ; Turčić, Petra ; Šošić Hrvoje ; Aralica, Gorana ; Babić, Damir ; Seiwerth, Sven ; Kaštelan, Željko ; Novak Kujundžić, Renata ; Wardega, Piotr et al. Targeting Tumor Markers with Antisense Peptides: An Example of Human Prostate Specific Antigen // International journal of molecular sciences, 20 (2019), 9; 2090, 20. doi: 10.3390/ijms20092090

Podaci o odgovornosti

Štambuk, Nikola ; Konjevoda, Paško ; Turčić, Petra ; Šošić Hrvoje ; Aralica, Gorana ; Babić, Damir ; Seiwerth, Sven ; Kaštelan, Željko ; Novak Kujundžić, Renata ; Wardega, Piotr ; Barać Žutelija, Jelena ; Gudelj Gračanin, Ana ; Gabričević, Mario

engleski

Targeting Tumor Markers with Antisense Peptides: An Example of Human Prostate Specific Antigen

The purpose of this paper was to outline the development of short peptide targeting of the human prostate specific antigen (hPSA), and to evaluate its effectiveness in staining PSA in human prostate cancer tissue. The targeting of the hPSA antigen by means of antisense peptide AVRDKVG was designed according to a three-step method involving: 1. The selection of the molecular target (hPSA epitope), 2. the modeling of an antisense peptide (paratope) based on the epitope sequence, and 3. the spectroscopic evaluation of sense–antisense peptide binding. We then modified standard hPSA immunohistochemical staining practice by using a biotinylated antisense peptide instead of the standard monoclonal antibody and compared the results of both procedures. Immunochemical testing on human tissue showed the applicability of the antisense peptide technology to human molecular targets. This methodology represents a new approach to deriving peptide ligands and potential lead compounds for the development of novel diagnostic substances, biopharmaceuticals and vaccines.

neoplasm ; prostate specific antigen ; biomarker ; antisense peptide ; immunohistochemistry ; nanomedicine

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

20 (9)

2019.

2090

20

objavljeno

1422-0067

10.3390/ijms20092090

Povezanost rada

Interdisciplinarne prirodne znanosti, Temeljne medicinske znanosti, Kliničke medicinske znanosti

Poveznice
Indeksiranost